New Ray Medicine International Holding Limited (HKG:6108)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.2050
-0.0070 (-3.30%)
At close: Apr 22, 2026
Market Cap42.53M -49.1%
Revenue (ttm)130.37M +38.8%
Net Income-20.07M
EPS-0.12
Shares Out200.62M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume24,000
Average Volume170,632
Open0.2100
Previous Close0.2120
Day's Range0.2050 - 0.2100
52-Week Range0.1910 - 0.5300
Beta-4.01
RSI46.49
Earnings DateMar 25, 2026

About HKG:6108

New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of pharmaceutical and related products in the People’s Republic of China. The company’s pharmaceutical products include levocarnitine injection for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, and parenteral nutrition; thoymosin α1 for injection to treat hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor rel... [Read more]

Sector Healthcare
Founded 2001
Employees 31
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6108
Full Company Profile

Financial Performance

In 2025, HKG:6108's revenue was 130.37 million, an increase of 38.78% compared to the previous year's 93.95 million. Losses were -20.07 million, -35.29% less than in 2024.

Financial Statements